Allon granted US patent for composition of matter
The allowed claims relate to the nucleic acid composition of Allon's drug candidates AL-108 and AL-208, which are both currently being evaluated in Phase II human efficacy trials. The Company has three Phase II clinical efficacy programs. AL-108 is being evaluated in two separate trials, one for Alzheimer's disease and another for schizophrenia related cognitive impairment. AL-208 is being evaluated as a treatment for the mild cognitive impairment associated with coronary artery bypass graft (MCI-CABG) surgery.
Most read news
Topics
Organizations
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.